The FDA will continue to assist in the accessibility of safe and effective digital health devices that might enhance patient access to needed healthcare." original link , called IDx-DR, is a software application program that uses an artificial intelligence algorithm to analyze images of the eye taken with a retinal cam called the Topcon NW400.
If the images are of sufficient quality, the software application offers the physician with one of two results: (1) "more than mild diabetic retinopathy found: describe an eye care professional" or (2) "unfavorable for more than moderate diabetic retinopathy; rescreen in 12 months." If a favorable result is identified, clients must see an eye care supplier for more diagnostic assessment and possible treatment as soon as possible.
The FDA assessed data from a medical study of retinal images gotten from 900 patients with diabetes at 10 primary care websites. The research study was created to examine how often IDx-DR could precisely identify patients with more than mild diabetic retinopathy. In the study, IDx-DR was able to correctly identify the existence of more than moderate diabetic retinopathy 87.
5 percent of the time. Patients who have a history of laser treatment, surgery or injections in the eye or who have any of the list below conditions ought to not be evaluated for diabetic retinopathy with IDx-DR: consistent vision loss, blurred vision, floaters, formerly detected macular edema, serious non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy or retinal vein occlusion.
IDx-DR is only designed to find diabetic retinopathy, including macular edema; it needs to not be utilized to detect any other illness or condition. Clients will still need to get a total eye evaluation at the age of 40 and at the age of 60 and also if they have any vision symptoms (for instance, consistent vision loss, blurred vision or floaters).